<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04919902</url>
  </required_header>
  <id_info>
    <org_study_id>EKV2020</org_study_id>
    <nct_id>NCT04919902</nct_id>
  </id_info>
  <brief_title>Prague Registry of Electric Cardioversion</brief_title>
  <acronym>PRAGUE-ECV</acronym>
  <official_title>Prague Registry of Electric Cardioversion for Supraventricular Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center observational registry follows contemporary efficacy and short-term&#xD;
      complications of elective electric cardioversion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Acute major complications</measure>
    <time_frame>Within 24 hours from the procedure</time_frame>
    <description>Major thromboembolic events or events related to cardioversion requiring unplanned hospitalisation (bleeding, severe bradycardia, anesthesia-related complications, heart failure etc)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subacute major complications</measure>
    <time_frame>24 hours to 30 days after the procedure</time_frame>
    <description>Major thromboembolic events or events related to cardioversion requiring unplanned hospitalisation (bleeding, severe bradycardia, anesthesia-related complications, acute heart failure etc), evaluated by structured phone call.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute minor complications</measure>
    <time_frame>Within 24 hours from the procedure</time_frame>
    <description>Minor procedure-related complications not requiring acute hospitalisation (asymptomatic bradycardia, post-anesthesia spasms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute efficacy</measure>
    <time_frame>Within 2 hours from the procedure</time_frame>
    <description>Presence of sinus rhythm on continous ECG (5-lead) monitoring</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>Atrial Arrhythmia</condition>
  <condition>Atrial Tachycardia</condition>
  <arm_group>
    <arm_group_label>Electric cardioversion</arm_group_label>
    <description>Patients who underwent elective cardioversion for atrial arrhythmia</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electric cardioversion</intervention_name>
    <description>Electric cardioversion in short sedation according to established clinical practice and indications</description>
    <arm_group_label>Electric cardioversion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hemodynamically stable patients scheduled for ambulatory electric cardioversion for atrial&#xD;
        arrhythmias based on established clinical indications.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive out-patients undergoing electric cardioversion for atrial fibrillation,&#xD;
             atrial tachycardia, or typical atrial flutter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable patients with acute conditions requiring unplanned hospitalization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Sramko, MD, PhD</last_name>
      <phone>+420731682681</phone>
      <email>marek.sramko@ikem.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Marek Sramko</investigator_full_name>
    <investigator_title>Head of the Department of Acute Cardiology</investigator_title>
  </responsible_party>
  <keyword>Anticoagulants</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Cardioversion</keyword>
  <keyword>NOAC</keyword>
  <keyword>DOAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

